The stock market’s recent rally continued Monday, with the major market indexes closing today at their highest levels since late August.
The gains came ahead of tomorrow morning’s release of the August consumer price index (CPI) – the last key piece of economic data for the Federal Reserve to consider ahead of its policy meeting next week. “The U.S. consumer price index, to be released on Tuesday, will likely show that August prices rose at an 8.1% pace over the year, compared to the July print at 8.5%,” says Jon Maier, chief investment officer at Global X ETFs. “If this number comes to pass, it will show that inflation is slowing some, albeit from very high levels.”
However, even with better CPI numbers, the Federal Reserve is likely “to continue on its path for another 75 basis-point hike later this month,” Maier adds. “The Fed is in a tough spot because employment reports suggest labor demand and employment growth have not slowed that much due to Fed actions thus far.”
Investor sentiment was also boosted by reports of Ukraine’s successful counteroffensive against Russian troops in the country’s northeastern Kharkiv region. “The start of the trading week was supposed to be all about the August inflation report, but Kyiv’s sudden momentum has many hoping that this moment is a turning point with the war against Russia,” says Edward Moya, senior market strategist at currency data provider OANDA.
By the close, the Nasdaq Composite was up 1.3% at 12,266, the S&P 500 Index gained 1.1% to 4,110, and the Dow Jones Industrial Average added 0.7% to 32,381. It was the fourth straight day of gains for all three indexes.
Other news in the stock market today:
- The small-cap Russell 2000 rose 1.2% to 1,906.
- U.S. crude futures climbed 1.1% to $87.78 per barrel.
- Gold futures edged up 0.7% to $1,740.60 an ounce.
- Bitcoin gained 5.3% to $22,406.20. (Bitcoin trades 24 hours a day; prices reported here are as of 4 p.m.)
- Bristol Myers Squibb (BMY) jumped 3.2% after the Food and Drug Administration (FDA) on Friday approved Sotyktu, the company’s oral treatment for moderate-to-severe psoriasis. “Most importantly, the much-debated label had no black-boxed warning, instead including a section titled ‘Potential Risks Related to JAK Inhibition,'” says UBS Global Research analyst Colin Bristow, who has a Neutral (Hold) rating on BMY stock. Black-box warnings are required by the FDA on drugs that have serious safety risks.
- Carvana (CVNA) spiked 15.4% after Piper Sandler analyst Alexander Potter upgraded the online auto retail stock to Overweight from Neutral, the equivalents of Buy and Hold, respectively. The analyst acknowledged that “bankruptcy is a real possibility” and that “used vehicle prices are falling,” but said the stock has “so much potential upside,” and that “investors should consider owning at least some CVNA.” Even with today’s pop, shares are down nearly 82% for the year-to-date.
Finding the Best Growth Stocks
As we’ve mentioned in this space more than once recently, markets are likely to stay volatile for the time being. In addition to three more Fed meetings this year, midterm elections are right around the corner. Therefore, it’s a safe assumption that many investors are taking a more defensive stance with their portfolios, leaning toward sectors like healthcare or utilities that tend to hold up better than others during times of uncertainty.
However, we’ve also made note of the fact that amid the broad market’s stiff selloff so far in 2022, notable discounts lurk – particularly among tech stocks, which have taken an outsized hit this year. But, “all tech is not created equal,” says Nancy Tengler, CEO and chief investment officer of asset management firm Laffer Tengler Investments. “There are times to chase cheap and times to stick with what’s working.” And for Tengler, what’s working now are cloud and cybersecurity stocks, which she believes will produce “reliable growth,” as companies ramp up their IT spending in both areas.
But these aren’t the only two areas of the beaten-down tech sector that create potential opportunities for investors right now. These 15 growth stocks have solid fundamental prospects and attractive valuations, and each are well-liked by analysts. Check them out.